In vitro activity of API-1252, a novel FabI inhibitor, against clinical isolates of Staphylococcus aureus and Staphylococcus epidermidis.
Karlowsky
James A
JA
Laing
Nancy M
NM
Baudry
Trish
T
Kaplan
Nachum
N
Vaughan
David
D
Hoban
Daryl J
DJ
Zhanel
George G
GG
D000900:Anti-Bacterial Agents / Q000737:chemistry / Q000494:pharmacology*; D001572:Benzofurans / Q000494:pharmacology*; D050753:Enoyl-(Acyl-Carrier-Protein) Reductase (NADH) / Q000037:antagonists & inhibitors*; D004791:Enzyme Inhibitors / Q000737:chemistry / Q000494:pharmacology*; D006801:Humans; D011753:Pyrones / Q000494:pharmacology*; D013203:Staphylococcal Infections / Q000188:drug therapy; D013211:Staphylococcus aureus / Q000187:drug effects* / Q000201:enzymology / Q000302:isolation & purification; D013212:Staphylococcus epidermidis / Q000187:drug effects* / Q000201:enzymology / Q000302:isolation & purification
C521531:API 1252; D000900:Anti-Bacterial Agents; D001572:Benzofurans; D004791:Enzyme Inhibitors; D011753:Pyrones; D050753:Enoyl-(Acyl-Carrier-Protein) Reductase (NADH)